Clozapine (Clozaril): The Gold Standard for Treatment-Resistant Schizophrenia

Clozapine (brand name: Clozaril, FazaClo) is a atypical antipsychotic (second-generation). Clozapine has the most complex pharmacological profile of any antipsychotic. It is a relatively weak dopamine D2 antagonist with fast dissociation kinetics (explaining its very low risk of extrapyramidal symptoms and tardive dyskinesia), a potent serotonin 5-HT2A antagonist, and has significant activity at D1, D4, 5-HT1A, 5-HT2C, muscarinic M1-M4, histamine H1, and alpha-1/alpha-2 adrenergic receptors. This broad profile likely explains both its superior efficacy and its extensive side effect burden. It is the ONLY antipsychotic with evidence for reducing suicidality (InterSePT trial) and the only one proven effective in treatment-resistant schizophrenia.

• Treatment-resistant schizophrenia (failed adequate trials of at least 2 other antipsychotics)
• Reducing suicidal behavior in schizophrenia or schizoaffective disorder

Common off-label uses:

• Treatment-resistant bipolar disorder
• Severe psychotic depression
• Parkinson's disease psychosis (very low doses)
• Severe aggression in developmental disorders

Start very low: 12.5 mg once or twice on day 1. Increase by 25-50 mg/day over 2 weeks. Target: 300-450 mg/day for most patients. Some need 600-900 mg/day. Therapeutic blood levels: 350-600 ng/mL (trough). Split dosing (BID/TID) if daytime sedation is problematic. Requires slow titration due to orthostatic hypotension and seizure risk.

May take 3-6 months for full response in treatment-resistant cases. Some improvement may be seen in 2-4 weeks. Patients who don't respond at 6 months with adequate levels are unlikely to respond.

• Sedation (often profound initially)
• Weight gain (the most of any antipsychotic, with olanzapine)
• Hypersalivation (paradoxically, despite anticholinergic activity — up to 30%)
• Constipation (can be severe)
• Tachycardia
• Metabolic syndrome
• Dizziness and orthostatic hypotension

• Agranulocytosis (potentially fatal drop in white blood cells — ~1% risk, requires mandatory blood monitoring via REMS program)
• Myocarditis and cardiomyopathy (highest risk in first 2 months — monitor for fever, chest pain, tachycardia, fatigue)
• Seizures (dose-dependent — ~3-5% at doses >600 mg)
• Severe constipation/ileus (can be fatal — clozapine causes profound gut dysmotility)
• Metabolic syndrome and diabetes
• Pulmonary embolism (2-5x increased risk)
• Rebound psychosis if stopped abruptly

CYP1A2 substrate — smoking decreases levels (smokers need higher doses; dose reduction when quitting). Fluvoxamine dramatically increases levels (2-5x — use with extreme caution). Caffeine moderately increases levels. Carbamazepine is contraindicated (both cause bone marrow suppression). Avoid drugs that cause agranulocytosis.

Category B. Limited data. Considered when benefits clearly outweigh risks and no alternative is effective. Neonatal complications possible.

Clozapine carries a black box warning for severe neutropenia (agranulocytosis). All patients must be enrolled in the Clozapine REMS (Risk Evaluation and Mitigation Strategy) program before dispensing. No ANC = no clozapine.

ANC Monitoring Thresholds (General Population):

• Green (Normal): ANC ≥ 1,500/µL — continue treatment, routine monitoring
• Yellow (Mild Neutropenia): ANC 1,000–1,499/µL — continue clozapine with increased monitoring frequency (at least 3x/week until ANC ≥ 1,500)
• Red (Severe Neutropenia): ANC < 1,000/µL — immediately discontinue clozapine, monitor daily until ANC ≥ 1,000, do not rechallenge unless benefit clearly outweighs risk

ANC Thresholds for Benign Ethnic Neutropenia (BEN): Updated in 2015 to address the higher rates of benign low ANC in patients of African, Middle Eastern, and some other ethnic backgrounds:

• Green (BEN): ANC ≥ 1,000/µL (lower threshold than general population)
• Yellow (BEN): ANC 500–999/µL
• Red (BEN): ANC < 500/µL — immediately discontinue

Monitoring Schedule:

• First 6 months: ANC monitoring weekly
• Months 6–12: ANC monitoring every 2 weeks (biweekly)
• After 12 months of stable ANC: ANC monitoring monthly

Key REMS Rules:

• No ANC result on file = no dispensing (pharmacies must verify before releasing medication)
• If monitoring is missed for more than the allowed gap, the monitoring schedule must restart from weekly
• All prescribers, pharmacies, and patients must be enrolled in the REMS registry
• Rechallenge after red requires hematology consultation and documented risk-benefit analysis

NEVER stop abruptly — rebound psychosis, cholinergic rebound (profuse sweating, nausea, diarrhea, headache), and confusion can occur within 1-2 days. Taper over weeks to months. If must discontinue rapidly (e.g., for agranulocytosis), an alternative antipsychotic should be started immediately.